


BUSINESS OVERVIEW

- Incorporated in 2011, Alpha IVF Group is today a fertility care specialist, currently operating in Malaysia and Singapore
 - Alpha International Women's Specialists Sdn Bhd in Selangor
 - Genesis Specialists Sdn Bhd in Penang
 - Alpha International Women's Specialists (Singapore) Pte Ltd
- Alpha IVF Group provides assisted reproductive services (ARS) with a primary focus on in-vitro fertilisation (IVF)
- The Group's Malaysia operations have provided IVF to foreign patients from Indonesia, China, Australia, Singapore, and other countries; Singapore operations mainly providing IVF services to Singapore patients



3
specialist centres

Patients Demographics by Revenue as at FYE 31 May 2023



1) Other countries include Hong Kong, Australia, Mauritius, USA and Vietnam
2) Excluding revenue from non-individuals such as private healthcare service operators (c. 4.0% of Total Revenue)

Total Staff Count: 144

Medical Specialists: 15

Other Healthcare Staff: 62

12
Obstetricians
& Gynaecologist

30 Embryologists

3
Others⁽³⁾


2 Geneticists

30 Nurses

3) Consists of 2 Anaesthesiologists and 1 Urologist


FINANCIAL INFORMATION

Revenue (RM '000)




Total revenue increased by 18.1% to RM65.9 million in FPE Oct 2023 (FPE Oct 2022: RM55.8 million), mainly driven by higher demand for ARS in Malaysia operations.

Gross Profit and Margins (RM '000)



Total GP grew by 19.8% to RM37.6 million in FPE Oct 2023 (FPE Oct 2022: RM31.4 million) due to growth in ARS in Malaysia operations with the higher number of IVF stimulation and pick-up performed and ancillary services rendered.

Profit After Tax and Margins (RM '000)




Normalised PAT grew 20.0% to RM21.2 million (FPE Oct 2022: RM17.7 million).

*Normalised profits and margins after netting off fair value gain on other investment of RM 11.3 million in Oct 2022.

Balance Sheet

Gearing Ratios



Dividend Policy


- Alpha IVF Group targets dividend distribution of at least 60% out of its consolidated profits after taxation attributable to shareholders annually

KEY INVESTMENT HIGHLIGHTS

1) UNIQUELY CRAFTED AND WELL-INTEGRATED INFRASTRUCTURE ESTABLISHED THROUGH ALPHA IVF'S STRONG FOUNDATION AND STRATEGIC PILLARS



2) TWO KEY INDUSTRY DRIVERS FUELLING ALPHA IVF'S GROWTH: (i) MEDICAL TOURISM BOOM IN SOUTHEAST ASIA (ii) RISING DEMAND FOR ARS DUE TO DECLINING FERTILITY RATE AND GOVERNMENT ARS INCENTIVES



- Government ARS Incentives**
- Employee Provident Fund (EPF) health withdrawal facility for fertility treatments
 - Income tax relief of up to RM10,000 for fertility treatments under the Budget 2023
 - Government co-funding scheme for Assisted Conception Procedures at public hospitals subsidizes up to 75% of ARS treatment costs for qualifying married couples, including:
 - (i) A maximum of 3 fresh and 3 frozen IVF cycles
 - (ii) 3 cycles of Intra-Uterine Insemination (IUI)
 - Government co-funding scheme for Preimplantation Genetic Testing for PGT-M and PGT-SR covering:
 - (i) Up to 75% in co-funding covering a maximum of 6 PGT-M or PGT-SR cycles from approved providers, which include Alpha Group in Singapore
 - MediSave for Assisted Conception Procedures and PGT-M/PGT-SR where patients may utilise up to SGD15,000 of their MediSave or their spouse's MediSave to fund their IVF and IUI procedures at both private and public assisted reproductive centres

3) HIGHLY ACCOMPLISHED TEAM COMPRISING IN-HOUSE AND EXTERNAL EXPERTS - POWERHOUSE OF HIGHLY QUALIFIED AND PIONEERING MEDICAL SPECIALISTS IN THE FIELD OF ARS

4) FOREFRONT OF MEDICAL AND LABORATORY ADVANCEMENTS THROUGH ONGOING INTERNAL RESEARCH AND COLLABORATION WITH OTHER RESEARCHERS

Actively participate in collaborations, carry out internal clinical studies and R&D in further pioneering assisted reproductive technologies to further enhance pregnancy rates.



Reputable conferences, seminars and societies Alpha IVF presented in



Note: (1) Since the commencement of the business and up to the LPD

5) POSSESS ROBUST IN-HOUSE CAPABILITIES TO SEAMLESSLY INTEGRATE CUTTING-EDGE TECHNIQUES AND TECHNOLOGIES TO FURTHER ENHANCE PREGNANCY RATES


6) STRONG TRACK RECORD AND CLINICAL EXPERIENCE SPANNING 12 YEARS IN THE PROVISION OF ARS, INDICATING EXCEPTIONAL BRAND EQUITY

In-House Techniques

- Pezzo-ICSI method** VS **Conventional ICSI method**
- Ova PRP** Ovarian rejuvenation using platelet-rich plasma (PRP) / **Endo PRP** Endometrium rejuvenation using platelet-rich plasma (PRP)

Advance IVF Technologies

- Ion Torrent™ Next Generation Sequencing (NGS)**
- Cryopreservation services** CRYOTECH Method
- AI Scoring - The Implantation Potential Score**
AI-enhanced embryo selection services
Microscopic images of each blastocyst uploaded into Alpha IVF's AI software and within minutes, a definitive AI Score will be generated based on its implantation potential and likelihood of pregnancy
- Time-lapse Monitoring System**
Combines the use of an incubator with a built-in camera and computer software to automatically capture images of the developing embryos at fixed intervals



Note: (1) Alpha Singapore commenced operations in November 2019

GROWTH STRATEGIES

1) DOMESTIC EXPANSION OF OPERATIONAL FACILITIES AND RESOURCES

SET-UP THREE FULL-FLEDGED FERTILITY CENTRES IN MALAYSIA

Alhaya

Licensed to operate private ambulatory care centre

5,560 sq ft

Kuala Lumpur

Early 2024

Specialist centre # 2

End FYE2025

Specialist centre # 3

End FYE2026

2) FOUR SATELLITE CLINICS ACROSS INDONESIA TO FACILITATE INDONESIAN PATIENTS FOR IVF TREATMENTS IN MALAYSIA; TWO FULL-FLEDGED FERTILITY CENTRES, ONE IN INDONESIA AND THE OTHER IN CAMBODIA/LAOS; TWO SALES OFFICES IN CHINA

(i) SATELLITE CLINICS ACROSS INDONESIA

- Satellite Clinic #1: 1,800 sq ft, End FYE 2025
- Satellite Clinic #2: 1,800 sq ft, End FYE 2026

(ii) FULL-FLEDGED FERTILITY CENTRES

- Full-Fledged Fertility centre in Laos or Cambodia: 8,000 sq ft, Fully-equipped IVF centre, End FYE 2025
- Full-Fledged Fertility centre in Indonesia: 10,660 sq ft, Fully-equipped IVF centre, End FYE 2025

(iii) SALES OFFICES

- Rental of Two New Sales Representative Office in China: 1,000 sq ft, Sales and Marketing, End of 2024

IPO STATISTICS AND UTILISATION OF PROCEEDS

ISSUE STRUCTURE: 1,458.0 million shares (30% of enlarged share capital)		
New shares 364.5 million		Offer-for-sale shares 1,093.5 million
Retail Offering 218.7 million	Institutional offering 1,239.3 million	
194.4 million to Public	607.5 million for Bumiputera investors approved by MITI	631.8 million for other institutional and selected investors

Detail	RMmil	Estimated time frame
Establishing new medical centres, satellite clinics and sales representative offices	72.8	Within 36 months
Expansion and upgrade of existing medical centres, facilities and corporate office	15.7	Within 36 months
Research and development	2.2	Within 36 months
General working capital	17.1	Within 36 months
General corporate purposes	2.6	Within 36 months
Defraying the listing expenses	6.2	Within 1 month
Total	118.6	